Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus; Guidance for Industry; Availability

By Drug Administration, Human Services Department, Food, Health · Nov 2, 2026, 11:00 PM CST

Read full article at Federal Register
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus." The guidance document provides blood establishments that collect blood and blood components, including Source Plasma, with FDA's recommendations for testing blood and blood components for hepatitis B virus (

Excerpt shown under fair-use limits. Full text remains with the original publisher.

People in this coverage

Explore their history and attributable record. Being mentioned does not imply endorsement.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

Factual ReportingThe article states the agency’s action without embellishment or persuasive language.

Citation of AuthorityThe piece references prior FDA documents to establish continuity and authority, reinforcing the official nature of the announcement.

Absence of Emotional LanguageThe language is technical and neutral, focusing on procedural details rather than emotive framing.

Context

AI analysis

Missing context

The announcement does not explain the specific reasons for updating the guidance at this time, such as recent changes in HBV epidemiology, advances in testing technology, or regulatory considerations. It also lacks information on how the new recommendations will be implemented by blood establishments, any timelines for compliance, and potential impacts on blood supply or donor eligibility.

Important context

The FDA is the federal agency responsible for regulating blood safety in the United States. Guidance documents such as this one provide non‑binding recommendations that influence industry practices and are often incorporated into regulatory expectations. By superseding earlier memoranda and guidances, the FDA consolidates and updates its recommendations to reflect current scientific knowledge and testing capabilities.

Opinion vs. reporting

AI analysis

The text is purely factual reporting of an FDA announcement; it contains no opinion or editorial commentary.